READY CAPITAL CORPORATION REPORTS THIRD QUARTER 2026 RESULTS

Ready Capital Corp (RC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 READY CAPITAL CORPORATION REPORTS THIRD QUARTER 2026 RESULTS New York, New York, November 5, 2026 / Globe Newswire / – Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC), a multi-strategy real estate finance company that originates, acquires, fin

Original reporting
Published Nov 5, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RC
Bearish
high confidence
Mentioned
$RC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RCBearishMed
01

Why it matters

The Q3 2026 earnings miss, highlighted by a GAAP loss of $0.40 per share, is likely to trigger a sell‑off, especially given the REIT sector's sensitivity to earnings quality.

02

Market read

First‑time disclosure of a quarterly loss for a listed REIT; traders can react to the earnings miss and balance‑sheet changes.

03

What to watch

The $225M senior secured note issuance and the retirement of $350M notes may strengthen the balance sheet despite the loss.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Ready Capital Corp (NYSE:RC) is a multi‑strategy real‑estate finance REIT that originated, acquired, financed and serviced lower‑to‑middle‑market commercial real‑estate loans.

Company-level read

Ticker impact

$RCBearishHigh confidence
Context

Ready Capital reported a GAAP loss of $0.40 per share and a distributable loss of $0.53 per share for Q3 2026, indicating weak earnings.

Expected impact

likely pressure as the market prices in the loss and weak guidance

Evidence & confidence

The disclosed losses are material and represent the first public release of the quarter's results, which typically moves the share price.

Market effects

Real estate finance REITs may face broader scrutiny after the loss report.

US REIT sector could see modest pullback in the short term.

Limited to US markets; no immediate global ripple.

Counterpoint

If the company successfully retires its 2026 maturities, cash flow could improve, offering a buying opportunity at a discounted price.

Key entities

  • Ready Capital Corp

    US‑listed REIT reporting Q3 2026 results.

Related articles

$RCMedAI 9/10

Ready Capital Corporation, through its subsidiary ReadyCap Holdings II, LLC, priced a private placement of $225.0 million in aggregate principal amount of…

Ready Capital Corp (RC) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed in its Current Report on Form 8-K filed on September 18, 2026, Ready Capital Corporation (the “ Company ”), through its subsidiary ReadyCap Holdings II, LLC (the “ Issuer ”), priced a private placement of $225.0 million in aggregate

$RCMed

Ready Capital (RC) Q2 2026 Earnings Call Transcript

Ready Capital (RC) reported Q2 2026 results on an earnings call. GAAP loss was $(0.63) per share, improving from $(1.25) in Q1. Distributable loss narrowed to $(0.47), or $(0.24) excluding realized asset-sale losses. Book value fell to $6.83. The company generated $1.9B liquidity to retire $1.7B debt and said 81% of its liquidity target is complete.

$RCMed

READY CAPITAL CORPORATION REPORTS SECOND QUARTER 2026 RESULTS

Ready Capital Corp (RC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 READY CAPITAL CORPORATION REPORTS SECOND QUARTER 2026 RESULTS New York, New York, August 6, 2026 / Globe Newswire / – Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC), a multi-strategy real estate finance company that originates, acquires, fina

$TMCIMed

Treace Medical (TMCI) Q3 2026 Earnings Call Transcript

Treace Medical (TMCI) reported Q3 2026 earnings, highlighting double-digit case volume growth and market share gains. The company expects 2026 product launches to expand its addressable market by $700M. Full-year revenue guidance was narrowed to $206M-$210M, up from previous guidance of $204M-$212M. The company is focusing on three key initiatives: driving adoption of new bunion systems, advancing Lapiplasty technology, and expanding into adjacent foot and ankle procedures.